Previous 10 | Next 10 |
home / stock / lly / lly articles
On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the dat...
Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its...
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL Int...
On Wednesday, Eli Lilly And Co (NYSE:LLY) announced that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 5 years by 35.98% on an annualized basis producing an average annual return o...
On Monday, Structure Therapeutics Inc. (NASDAQ:GPCR) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase ...
On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY). QurAlis has grant...
Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling p...
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...